Cargando…
Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older
BACKGROUND: It is estimated that approximately 50% of patients with hepatitis C virus (HCV) infection in Japan are currently over 75 years old. However, patients aged ≥ 75 years are typically underrepresented in clinical trials of direct-acting antivirals. This study aimed to evaluate the efficacy a...
Autores principales: | Komaki, Yuri, Ozono, Yoshinori, Nakamura, Kenichi, Iwakiri, Hisayoshi, Hasuike, Satoru, Sueta, Mitsue, Miike, Tadashi, Yamamoto, Shojiro, Uto, Hirofumi, Kusumoto, Kazunori, Ochiai, Toshimasa, Kato, Junya, Komada, Naoto, Kuroki, Kazuo, Eto, Toshiharu, Shigehira, Masafumi, Hirono, Shuichi, Nagata, Kenji, Kawakami, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052496/ https://www.ncbi.nlm.nih.gov/pubmed/35484503 http://dx.doi.org/10.1186/s12876-022-02284-z |
Ejemplares similares
-
Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1
por: Ozono, Yoshinori, et al.
Publicado: (2017) -
Inflammatory Hepatocellular Adenoma Mimicking Focal Nodular Hyperplasia That Grew during Pregnancy and Changed Its Appearance on Magnetic Resonance Imaging after Delivery
por: Hasuike, Satoru, et al.
Publicado: (2023) -
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021) -
Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
por: Liu, Xiaoqing, et al.
Publicado: (2021) -
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
por: Cotter, Thomas G, et al.
Publicado: (2019)